Related Experiment Video
Updated: Jun 26, 2026
11:19
Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
[Palliative sedation in pediatric oncology]
Julia Kovacs1, Nazar Casey, Dietmar Weixler
1Fachärztin für Anästhesie und Pädiatrie, St. Anna Kinderspital, Wien, Osterreich. julia_kovacs@gmx.de
Wiener Medizinische Wochenschrift (1946)
|January 24, 2009
Summary
Palliative sedation therapy was necessary for a pediatric patient with rhabdomyosarcoma experiencing severe bone and lung metastases. This case discusses treatment nuances and the psychological aspects of end-of-life care in children.
Area of Science:
- Pediatric Oncology
- Palliative Care
- Medical Ethics
Background:
- Rhabdomyosarcoma is a rare childhood solid tumor.
- Bone and lung metastases can cause severe pain.
- Palliative sedation may be indicated for intractable suffering.
Observation:
- A pediatric patient with rhabdomyosarcoma developed extensive bone and lung metastases.
- Severe pain necessitated palliative sedation therapy.
- The case highlights the complexities of end-of-life care in pediatric oncology.
Findings:
- Palliative sedation was successfully implemented in a pediatric patient with rhabdomyosarcoma.
- Drug selection for palliative sedation in children differs from adults.
- The psychological impact on the dying child and family is a critical consideration.
Implications:
- This case underscores the importance of tailored palliative care strategies for pediatric cancer patients.
- Understanding the unique pharmacological and psychological needs of dying children is crucial.
- Further research into pediatric palliative sedation protocols is warranted.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Parenteral Anesthetics: Overview
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...